We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Boston Scientific to Acquire Bayer’s Interventional Division

By HospiMedica International staff writers
Posted on 25 May 2014
Print article
In a move to significantly expand its portfolio of solutions for peripheral interventions, Boston Scientific (Natick, MA, USA) has entered into a definitive agreement to acquire the Interventional Division of Bayer (Leverkusen, Germany) for USD 415 million in cash.

The acquisition is expected to strengthen Boston Scientific’s peripheral interventions business and support the company’s strategy to expand the portfolio of peripheral vascular disease solutions, especially in the peripheral atherectomy and thrombectomy categories. Upon completion of the transaction, Bayer Interventional will become part of the existing Boston Scientific peripheral interventions business. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second half of 2014.

The transaction includes the AngioJet Thrombectomy System, which breaks apart and removes blood clots from within blood vessels, and the Fetch 2 Aspiration Catheter, which is used for small vessels when a manual thrombectomy device is preferred to resolve small, fresh thrombi in the peripheral and coronary arteries. The deal also includes the JetStream Atherectomy System, a versatile debulking solution for breaking apart and removing multiple lesion morphologies—from thrombus to challenging calcium deposits—from upper and lower extremity peripheral arteries.

“We expect this acquisition will help fuel continued growth for the company and we are looking forward to welcoming the team from Bayer Interventional to Boston Scientific,” said Mike Mahoney, President and CEO of Boston Scientific. “These technologies help physicians save both limbs and lives, and we believe this transaction will enable us to reach more effectively the greater than 27 million patients worldwide who suffer from the debilitating effects of peripheral vascular disease.”

“With this sale, our medical care division can concentrate on innovation and growth in radiology and diabetes care, where we already have a strong presence,” said Olivier Brandicourt, MD, CEO of Bayer HealthCare.

“The addition of Bayer Interventional will expand our commercial footprint and enhance our ability to provide physicians and healthcare systems with a complete portfolio of solutions to treat challenging vascular conditions,” added Jeff Mirviss, president of peripheral interventions at Boston Scientific. “We believe this acquisition will accelerate the growth of our Peripheral Interventions business and strengthen our position as a global leader in peripheral therapies.”

Related Links:

Boston Scientific
Bayer


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Vibrating Mesh Nebulizer
Aerogen Solo

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.